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The experiments reported in this study tested the hypothesis that tight binding dopamine (DA) reuptake inhibitors might act as cocaine antagonists. 
Binding studies demonstrated that the high affinity dopamine reuptake inhibitor, I-[2-[bis(efluorophenyl)methoxy]ethyl]-4_raz- 
ine (GBR12909) produced a wash-resistant inhibition of the DA transporter in rat striatal membranes as labeled by PHIcocaine or PH]l-[2-(diphen- 
yl-methoxy)ethyl]-4-(3-phenylpropyl)piperazine (PH]GBR12935), indicative of tight binding. In vivo microdialysis experiments showed that admin- 
istration of 25 mg/kg GBR12909 to rats produced a modest, but not statistically significant, increase in the extracellular levels of striatal DA, while 
this same dose of GBR12909 inhibited the ability of cocaine to elevate xtracellular DA levels by 64%. These data suggest hat tight binding DA 
reuptake blockers may provide a fruitful approach for developing a cocaine antagonist. 
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1. INTRODUCTION 
Cocaine, a major drug of abuse, is thought to pro- 
duce its effects primarily by inhibiting the reuptake of 
biogenic amines [ 11. Although cocaine inhibits the reup- 
take of norepinephrine and serotonin, its ability to in- 
hibit the reuptake of dopamine (DA) is thought to be 
the main neurochemical mechanism responsible for its 
addictive and euphorogenic properties [2]. Several ines 
of evidence support the DA hypothesis, including a ma- 
jor role of dopaminergic systems in reward mechanisms 
[3] and a correlation between the potency of cocaine- 
like drugs to inhibit DA reuptake and their potency as 
self-administered agents in animals [2]. 
inhibitor of DA reuptake [9] which is not reported to 
have cocaine-like effects in humans [lo]. Interestingly, 
whereas mazindol and nomifensine are self- 
administered by animals [ 1 l-l 31, bupropion is not [ 141. 
To reflect these differences, we term DA-reuptake in- 
hibitors abused by humans ‘type l’, and those not abus- 
ed ‘type 2’. 
However, not all DA reuptake inhibitors are abused 
by humans. For example, mazindol, nomifensine and 
bupropion are clinically effective antidepressants which 
have not been reported to have euphorogenic effects in 
humans [4-81. Moreover, benztropine, a drug widely 
prescribed for treatment of Parkinson’s disease and for 
treatment of extrapyramidal side-effects resulting from 
administration of antipsychotic drugs, is also a potent 
The ability of agents to inhibit DA reuptake in vitro 
or be self-administered by animals does not always 
predict their abuse liability in humans [4-81. Published 
data suggest hat their ability to elevate extracellular 
levels of DA (ECDA) in vivo does [ 151. For example, 
cocaine and amphetamine, as well as other drugs of 
abuse, produce large elevations in ECDA as measured 
by the technique of in vivo microdialysis [ 151. In con- 
trast, type 2 agents such as nomifensine and benz- 
tropine produce much lower and inconsistent elevations 
of ECDA levels [16]. 
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Based on these data, we hypothesized that, defining 
elevation of ECDA as the dependent variable (which 
does not specify a mechanism of action), type 1 and 
type 2 agents are full and partial agonists, respectively. 
A direct prediction of this hypothesis is that occupation 
of the DA reuptake complex by a type 2 reuptake in- 
hibitor should attenuate the effects of cocaine, and 
potentially be useful in humans as antagonists of type 1 
agents. A competitive antagonist would be of limited 
value, since a person would simply self-administer more 
of the type 1 agent, overcoming the inhibition, and in- 
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creasing the risk of peripheral side-effects uch as car- 
diac arrhythmias. Alternatively, administration of a 
tight binding (slowly dissociating) type 2 agent should 
produce an insurmountable (noncompetitive) inhibition 
over the time period which it remains bound to the re- 
uptake complex. 
serted, 20 pl samples were collected every 20 min into polyethylene 
tubes containing 10 pl perchloric acid (1 M). Immediately after collec- 
tion samples were injected into a high pressure liquid chromatography 
system and analyzed using electrochemica1 detection. After 2 h, 3 
baseline samples were collected and then the pharmacological treat- 
ment was started. 
To test this hypothesis, we chose GBR12909, a potent 
DA reuptake inhibitor [9] which does not by itself pro- 
duce large elevations in ECDA [ 171. Its high affinity for 
the DA reuptake complex [9] and our experiments ug- 
gesting that it binds tightly to the DA reuptake complex 
[ 181 led us to select it as a prototypic type 2 agent. The 
results reported here demonstrate that administration 
of GBR12909 to rats: (i) produces a pseudoirreversible 
inhibition of t3H]cocaine and [3H]GBR12935 binding 
to the DA transporter assayed using striatal membranes 
in vitro; and (ii) antagonizes the ability of cocaine to 
elevate ECDA in vivo. 
Treatment consisted of either GBR12909 (25 mg/kg) or saline in- 
jected i.p. 1 h afterwards, the same rats were infused through the pro- 
be with cocaine (1 mM) dissolved in aCSF. After 20 min, perfusion of 
the probe with normal aCSF was resumed and samples were collected 
for an additional hour. 
The HPLC system used in these studies included a BAS LC-4B elec- 
trochemical detector with a glassy carbon working electrode set at 
0.730 V. A Brownlee 10 cm reversed-phase Cl8 column, and a mobile 
phase comprised of sodium acetate (2.0 g). citric acid (3.0 g), sodium 
octylsulphate (350 mg), EDTA (88 mg) and methanol (70 ml) in 
distilled water (1 liter) were used to isolate the DA in the samples. 
2.4. Statistics 
Statistical differences among groups in the ligand binding ex- 
periments were determined using the Student’s t-test. In vivo micro- 
dialysis data were analyzed by one-way analysis of variance 
(ANOVA). 
2. MATERIALS AND METHODS 
2.1. Preparation of striatal membranes 
2.5. chemicals 
GBR12909 (25 mg/kg) dissolved in dimethylsulfoxide 
(DMSO)/saline was administered i.p. to 3 male Sprague-Dawley rats 
while 3 other control rats received vehicle. One hour later the rats 
were sacrificed and the caudate nuclei dissected and stored at - 7O’C. 
On the day of assay, caudate nuclei were homogenized with a 
polytron in ice-cold 55.2 mM sodium phosphate buffer, pH 7.4 (buf- 
fer 1). The homogenate was centrifuged for 10 min at 39000 x g, at 
4°C. The pellets were resuspended in ice-cold buffer and recentrifug- 
ed. The pellets were then resuspended in ice-cold buffer 1 for the 
[‘H]GBR12935 binding assay (approximately 100 ,ug protein/ml), or 
with ice-cold 25 mM sodium phosphate buffer, pH 7.4, for the [‘HI- 
cocaine binding assay (approximately 1.2 mg protein/ml). 
[3H]GBR12935 (spec. act. = 30.5 Ci/mmol) and [‘H](- )-cocaine 
(spec. act. = 28.5 Ci/mmol) were purchased from New England 
Nuclear. Unlabeled (-)-cocaine was supplied by Dr Rapaka of 
NIDA. GBR12909-(HCl)2 was synthesized in Laboratory of Medical 
Chemistry, NIDDK, as described [22). Other reagents were purchased 
from Sigma Chemical Co. 
3. RESULTS 
2.2. Lrgand binding assays 
In the first series of experiments, GBR12909 
(25 mg/kg) was administered to rats. Caudates were 
dissected 60 min after the injection, and striatal mem- 
branes were prepared as described in section 2. As 
shown in fig.1, this dose of GBR12909 produced a 
To label 13H]cocaine binding sites [19], striatal membranes were in- 
cubated in 12 x 75 mm polystyrene test tubes for 20-60 min at 0°C 
(equilibrium) in 25 mM sodium phosphate buffer, pH 7.4, with 
10 nM [‘HIcocaine (spec. act. = 28.5 Ci/mmol) in a final vol. of 
1 ml. The nonspecific binding was determined using lOpM cocaine. 
Incubations were terminated by rapid filtration, using a single mani- 
fold, over Whatman GF/B filters presoaked in 1% polyethylenimine, 
followed by a wash with 7 ml ice-cold 25 mM phosphate buffer, pH 
7.4, containing 400 mM NaCl. 
Binding sites associated with the DA transporter were also labeled 
with [‘H]GBR12935 [20]. The membrane suspensions were incubated 
in a final vol. of 1 ml for 2 h at 0°C (equilibrium) in 55 mM sodium 
phosphate buffer containing EDTA (10 FM), EGTA (10 FM), chymo- 
statin (2.5 &g/ml) and leupeptin (2.5 ,ug/ml). Nonspecific binding was 
determined by incubations in the presence of 1 /IM GBR12909. In- 
cubations were terminated by rapid filtration through Whatman 
GF/B filters presoaked in 2% polyethylenimine. 
2.3. In vivo mrcrodialysts 
Male Sprague-Dawley rats (300-350 g, Taconic Farms, MD) were 
anesthetized with chloral hydrate 400 mgfkg and placed in a stereo- 
taxic frame. Anesthesia was maintained at a level throughout each ex- 
periment whereby cornea] reflexes were abolished. A 3 mm micro- 
dialysis probe (Carnagie Medicine) was lowered into the striatum at 
stereotaxic oordinates of AP + 9.9, ML + 3.2, DV + 3.0 [21]. Ar- 
tificial CSF (aCSF) containing NaCl (8.6 g), KC1 (0.3 g), 
CaCl2.2H20 (0.335 g) and ascorbic acid (0.004 g) in distilled water 
(1 liter) was pumped through the probe at a flow rate of 1 .O pl/min 
using a microinfusion pump (CMA/lOO). After the probe was in- 
Fig. 1. GBR12909 (25 mg/kg) or vehicle was administered to rats and, 
as described in section 2, striatal membranes were prepared 60 min 
later. The specific binding of 9.6 nM [‘HIcocaine and 2.5 nM [3H]- 
GBRl2935 was determined as described in section 2. The results are 
reported as the percent of control -+ SD (n = 3). *P<O.OOl when 
compared to control. 
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ATTENUATION OF COCAINE BY GBR 12909 
Fig.2. The effects of saline or GBR12909 (25 mg/kg) administered 
i.p. to rats on the levels of striatal extracellular DA produced by co- 
caine (1 mM) delivered through the microdialysis probe are reported 
above. The effect of a drug was calculated as a percent of the preex- 
isting baseline value. One-way analysis of variance revealed a signifi- 
cant difference among treatment groups (F = 15.6, df 3/18, 
P<O.OOl). Duncan’s multiple range tests indicated that the increase 
in extracellular DA induced by cocaine was significantly different 
from that induced by saline (P<O.Ol) as well as the GBR12909 + co- 
caine group (P<O.Ol). Each value is the mean f SE (n = 5). 
74.7% and 69.6% inhibition of [3H]GBR12935 and 
[3H]cocaine binding, respectively. Subsequent ex- 
periments demonstrated that administration of 
GBR12909 (25 mg/kg) inhibited [3H]GBR12935 bind- 
ing by decreasing the B,,, from 10900 to 
5200 fmol/mg protein, and increasing the & from 2.0 
to 6.6 nM. Moreover, washing membranes an addi- 
tional two times by centrifugation and resuspension did 
not reverse these changes in the B,,, or & (data not 
shown). 
Administration of 25 mg/kg GBR12909 to rats pro- 
duced a stable, modest, and long-lasting (at least 6 h) 
elevation of ECDA levels (221% of control) which did 
not achieve statistical significance. Administration of 
100 mg/kg GBR12909 increased ECDA levels to 357 f 
179 (mean + SD, n = 3) percent of control (data not 
shown). As reported in fig.2, administration of cocaine 
(1 mM) through the microdialysis probe increased 
ECDA levels 686% over baseline levels. However, in 
rats pretreated with GBR12909 (25 mg/kg), cocaine in- 
creased ECDA levels only 248% over the preexisting 
GBR12909-induced baseline, leading to the observed 
63.8% reduction in the ability of cocaine to elevate 
ECDA levels. 
4. DISCUSSION 
Data presented in this study demonstrate that ad- 
ministration of GBR12909 to rats produces a wash- 
resistant inhibition of both [3H]GBR12935 and [3H]~o- 
Caine binding. Saturation binding studies with [3H]- 
GBR12935 demonstrated that the inhibition was due to 
a decrease in the B,,,, as well as an increase in the &. 
Further investigation revealed that the increase in the 
Kd was due to GBR12909 carried over into the assay, 
and that washing the membranes by repeated cen- 
trifugation and resuspension did not remove the 
GBR12909 (data not shown). Similar experiments were 
not done with [3H]cocaine because of the large amounts 
of membrane protein required by that assay. Our inter- 
pretation of these results is that the decrease in the B,,, 
results from GBR12909 tightly binding to the reuptake 
complex, and that the increase in the Kd results from 
free GBR12909. It is also possible that a higher fraction 
of binding sites were occupied in vivo, but not detected 
in vitro due to dissociation of GBR12909. 
We found that administration of GBR12909 at a dose 
sufficient to tightly bind to about 50% of the DA trans- 
porters, produced modest increases in ECDA levels, 
which did not achieve statistical significance, and which 
were much lower than the increases in ECDA levels 
typically produced by cocaine. Consistent with persis- 
tent occupation of the DA transporter by GBR12909, 
the ECDA levels remained elevated for at least 6 h. 
Moreover, GBR12909 attenuated the ability of cocaine 
to increase ECDA levels. The occurrence of local 
anesthetic effects at higher cocaine concentrations com- 
plicates the generation of complete dose-response 
curves, thus it may not be possible to prove the non- 
competitive nature of the inhibition. 
The ability of GBR12909 to antagonize the ability of 
cocaine to increase ECDA levels by binding tightly to 
the DA transporter suggests that it might also an- 
tagonize the actions of other drugs of abuse. For exam- 
ple, amphetamine must be transported by the DA reup- 
take complex into the DA nerve terminal to release DA. 
Similarly, to the extent that the psychotomimetic and 
addictive properties of phencyclidine (PCP) relate to in- 
hibition of DA reuptake [23,24], GBR12909 may act as 
a PCP antagonist. Future experiments will test this 
hypothesis. 
Psychopharmacological treatment of the cocaine 
abuser is a complex matter under investigation by many 
research groups. Although administration of anti- 
depressants uch as desipramine and mazindol [25-271 
to humans helps attenuate the craving for cocaine, this 
effect takes several weeks to develop, and does not ap- 
pear related to a direct antagonism of the cocaine. The 
demonstration that GBR12909 acts as a cocaine an- 
tagonist, in a system measuring the neurotransmitter 
considered to be the brain’s addictive signal, suggests 
that it might act as a cocaine antagonist in humans, 
which would be of considerable value in the treatment 
of cocaine abuse and addiction. Even if GBR12909 
were found to be unsuitable for use in humans, we 
believe that the strategy of using tight binding type 2 
DA reuptake inhibitors represents a potentially fruitful 
approach for developing a cocaine antagonist. 
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